Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 71 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBCActive, not recruitingNCT03567720Phase 2
- Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before SurgeryActive, not recruitingNCT03565783Phase 2
- Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)CompletedNCT03564691Phase 1
- Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerActive, not recruitingNCT03563248Phase 2
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLCStatus unknownNCT03557411Phase 2
- Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the CervixCompletedNCT03556839Phase 3
- A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT03551782Phase 1
- NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial CarcinomaActive, not recruitingNCT03549715Phase 1/2
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersCompletedNCT03547037Phase 1
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2
- SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck CarcinomaActive, not recruitingNCT03546582Phase 2
- Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesActive, not recruitingNCT03546426Phase 1
- CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03546361Phase 1
- A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.CompletedNCT03545971Phase 1
- Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)Active, not recruitingNCT03544736Phase 1/2
- Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1
- Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNATerminatedNCT03544099Phase 2
- Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation TherapyCompletedNCT03543189Phase 1/2
- Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)Status unknownNCT03542461Phase 3
- Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung CancerActive, not recruitingNCT03540420Phase 2
- Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian CancerStatus unknownNCT03539328Phase 2
- A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
- Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line TreatmentStatus unknownNCT03536780Phase 2
- Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)Active, not recruitingNCT03534635Phase 2
- Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2
- An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03533283Phase 1/2
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT03532217Phase 1
- A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsActive, not recruitingNCT03530397Phase 1
- Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderStatus unknownNCT03529890Phase 2
- Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid TumorsStatus unknownNCT03529526Phase 1
- Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerActive, not recruitingNCT03528694Phase 3
- Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2
- Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCStatus unknownNCT03527251Phase 1
- Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCActive, not recruitingNCT03527108Phase 2
- Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerActive, not recruitingNCT03526432Phase 2
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1
- Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid TumorsCompletedNCT03525925Phase 1
- A Study of CS1002 in Subjects with Advanced Solid TumorsCompletedNCT03523819Phase 1
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
- A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyActive, not recruitingNCT03520491Phase 2
- A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal CarcinomaCompletedNCT03519295Phase 2
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedNCT03518320Phase 1
- A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedNCT03517488Phase 1
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
- Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast CancerActive, not recruitingNCT03515798Phase 2
- PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)CompletedNCT03514719Phase 1
- Paclitaxel-Avelumab for AngiosarcomaStatus unknownNCT03512834Phase 2
- Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaActive, not recruitingNCT03512405Phase 1/2
- Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)CompletedNCT03510871Phase 2
- Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsTerminatedNCT03509584Phase 1
- Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
- A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03505996Phase 2
- Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]Active, not recruitingNCT03504163Phase 2
- Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial CancerStatus unknownNCT03503786Phase 2
- Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingNCT03502733Phase 1
- Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Status unknownNCT03502629Phase 2
- Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03498378Phase 1
- Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinWithdrawnNCT03498222Phase 1
- A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid TumorsCompletedNCT03495323Phase 1
- Pembrolizumab and Paclitaxel in Hypermutated Breast CancerCompletedNCT03492918Phase 2
- Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid TumorsStatus unknownNCT03491631Phase 1
- K-Basket, Avelumab, Biomarker-driven, Advanced Solid TumorStatus unknownNCT03491345Phase 2
- SHR-1210 in Combination With GEMOX in Patients With Advanced BTCCompletedNCT03486678Phase 2
- Avelumab/Gemcitabine in Sarcomatoid RCCTerminatedNCT03483883Phase 1
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive, not recruitingNCT03482102Phase 2
- A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic CancerTerminatedNCT03481920Early Phase 1
- Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT03480672Phase 2
- Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTCCompletedNCT03478488Phase 3
- Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate CancerWithdrawnNCT03477864Phase 1
- A Study of CS1003 in Subjects With Advanced Solid TumorsCompletedNCT03475251Phase 1
- TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)CompletedNCT03475134Phase 1
- Safety and Tolerability of SHR-1316 in Subjects With Advanced TumorsStatus unknownNCT03474289Phase 1
- Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA PatientsCompletedNCT03473574Phase 2
- Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)CompletedNCT03472274Phase 2
- Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic MelanomaCompletedNCT03472027Phase 1
- Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHLTerminatedNCT03471351Phase 1
- Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErCompletedNCT03469960Phase 3
- Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's SarcomaStatus unknownNCT03469804Phase 2
- Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell CarcinomaCompletedNCT03469713Phase 2
- Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid TumorsStatus unknownNCT03468751Phase 1
- Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast CancerCompletedNCT03464942Phase 2
- Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial CarcinomaCompletedNCT03464734Phase 2
- A Study of BCD-135 in Patients With Advanced Solid TumorsStatus unknownNCT03464032Phase 1
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic CancerActive, not recruitingNCT03463460Phase 2
- Immunotherapy + Radiation in Resectable Soft Tissue SarcomaCompletedNCT03463408Early Phase 1
- The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCLActive, not recruitingNCT03463057Phase 2
- Tolerance and Pharmacokinetics of TQB2450Status unknownNCT03460457Phase 1
- CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCompletedNCT03454451Phase 1
- Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar CancersCompletedNCT03452332Phase 1
- Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCCStatus unknownNCT03450967Phase 2
- Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)Active, not recruitingNCT03448835Phase 2
- ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral MetastasesWithdrawnNCT03448666Phase 2
- Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.Status unknownNCT03447678Phase 2
- Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)CompletedNCT03446547Phase 2
- Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young AdultsCompletedNCT03445858Early Phase 1
- Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceActive, not recruitingNCT03443856Phase 2
- A Phase 1/2 Study of FS118 in Patients With Advanced MalignanciesTerminatedNCT03440437Phase 1/2